Ikaros proteins are identified to serve as suppressors in diverse types of lymphoma or leukemia (Heizmann et al., 2018; Chan, 2019), whereas they are overexpressed in other malignancies to maintain cancer cell proliferation and survival, such as in malignant plasma cells, monoclonal gammopathy of undetermined significance, and multiple myeloma (MM) (Cippitelli et al., 2021). This evidence concerns the gene IKZF1 and Miyoshi myopathy.